- Current status of red blood cell manufacturing in 3D culture and bioreactors
-
Kweon S, Kim S, Baek EJ
- KMID: 2541982
- Blood Res.
- 2023 Apr;58(S1):46-51.
- doi: 10.5045/br.2023.2023008
Owing to donor-related issues, blood shortages and transfusion-related adverse reactions have become global issues of grave concern. In vitro manufactured red blood cells (RBCs) are promising substitutes for blood donation.... -
- CITED
-
- Close
- SHARE
-
- Close
- Transfusion support in hematopoietic stem cell transplantation
-
Jekarl DW, Kim JK, Han JH, Lee H, Yoo J, Lim J, Kim Y
- KMID: 2541975
- Blood Res.
- 2023 Apr;58(S1):1-7.
- doi: 10.5045/br.2023.2023004
Transfusion support for hematopoietic stem cell transplantation (HSCT) is an essential part of supportive care, and compatible blood should be transfused into recipients. As leukocyte antigen (HLA) matching is considered... -
- CITED
-
- Close
- SHARE
-
- Close
- Practical issues in CAR T-cell therapy
-
Byun JM
- KMID: 2541977
- Blood Res.
- 2023 Apr;58(S1):11-12.
- doi: 10.5045/br.2023.2023015
Chimeric antigen receptor (CAR) T-cell therapy presents a revolutionary advancement in personalized cancer treatment. During the production process, the patient's own T-cells are genetically engineered to express a synthetic receptor... -
- CITED
-
- Close
- SHARE
-
- Close
- Mycosis fungoides and Sézary syndrome
-
Lee H
- KMID: 2541985
- Blood Res.
- 2023 Apr;58(S1):66-82.
- doi: 10.5045/br.2023.2023023
Mycosis fungoides (MF) and Sézary syndrome (SS) are a distinct disease entity of cutaneous T-cell lymphoma with heterogenous clinical features and prognosis. MF mainly involves skin and usually shows an... -
- CITED
-
- Close
- SHARE
-
- Close
- Transfusion thresholds: the need for a patient-centered approach in hematologic disorders that require chronic transfusion therapy
-
Kim HJ, Hwang SH, Oh HB, Ko DH
- KMID: 2541976
- Blood Res.
- 2023 Apr;58(S1):8-10.
- doi: 10.5045/br.2023.2023009
Transfusion is an essential life-sustaining treatment for many patients. However, unnecessary transfusion has been reported to be related to worse patient outcomes. Further, owing to the recent pandemic, blood supply... -
- CITED
-
- Close
- SHARE
-
- Close
- T-large granular lymphocytic leukemia
-
Park SH, Lee YJ, Kim Y, Kim HK, Lim JH, Jo JC
- KMID: 2541983
- Blood Res.
- 2023 Apr;58(S1):52-57.
- doi: REVIEW ARTICLE
T-cell large granular lymphocyte (T-LGL) leukemia is characterized by clonal expansion of cytotoxic T cells resulting in cytopenia. The proliferation of clonal LGLs is caused by prolonged antigenic stimulation, which... -
- CITED
-
- Close
- SHARE
-
- Close
- Novel therapeutic strategies for essential thrombocythemia/polycythemia vera
-
Yoon SY, Won JH
- KMID: 2541986
- Blood Res.
- 2023 Apr;58(S1):83-89.
- doi: 10.5045/br.2023.2023013
Myeloproliferative neoplasms (MPNs) are clonal disorders of hematopoietic stem cells; these include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). MPNs are inflammatory cancers, wherein the malignant clone generates... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplantation
-
Uhm J
- KMID: 2541989
- Blood Res.
- 2023 Apr;58(S1):109-113.
- doi: 10.5045/br.2023.2023054
The treatment outcomes of chronic myeloid leukemia in chronic phase (CML-CP) have dramatically improved with comparable life-expectancy to average of general population in tyrosine kinase inhibitor (TKI) era. However, less... -
- CITED
-
- Close
- SHARE
-
- Close
- Prognostication in myeloproliferative neoplasms, including mutational abnormalities
-
Hong J
- KMID: 2541981
- Blood Res.
- 2023 Apr;58(S1):37-45.
- doi: 10.5045/br.2023.2023038
Increasing knowledge of the molecular features of myeloproliferative neoplasms (MPNs) is being combined with existing prognostic models based on clinical, laboratory, and cytogenetic information. Mutation-enhanced international prognostic systems (MIPSS) for... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia
-
Han JJ
- KMID: 2541984
- Blood Res.
- 2023 Apr;58(S1):58-65.
- doi: 10.5045/br.2023.2023035
Patients with chronic myeloid leukemia (CML) in the chronic phase receiving tyrosine kinase inhibitor (TKI) therapy are expected to have long-term survival outcomes comparable to those of the general population.... -
- CITED
-
- Close
- SHARE
-
- Close
- Plasmacytoid dendritic cell neoplasms
-
Lee YJ, Kim Y, Park SH, Jo JC
- KMID: 2541987
- Blood Res.
- 2023 Apr;58(S1):90-95.
- doi: 10.5045/br.2023.2023052
Plasmacytoid dendritic cells (pDCs) are type I interferon-producing cells that modulate immune responses. There are two types of pDC neoplasms: 1) mature pDC proliferation (MPDCP) associated with myeloid neoplasm and... -
- CITED
-
- Close
- SHARE
-
- Close
- Novel therapeutics for myelofibrosis
-
Lee SE
- KMID: 2541978
- Blood Res.
- 2023 Apr;58(S1):13-19.
- doi: 10.5045/br.2023.2023012
Myelofibrosis (MF) includes primary MF, post-essential thrombocythemia MF, and post-polycythemia vera MF. MF is a progressive myeloid neoplasm characterized by ineffective clonal hematopoiesis, extramedullary hematopoiesis, a reactive bone marrow environment... -
- CITED
-
- Close
- SHARE
-
- Close
- Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase
-
Choi EJ
- KMID: 2541980
- Blood Res.
- 2023 Apr;58(S1):29-36.
- doi: 10.5045/br.2023.2023017
The prognosis of patients with chronic phase (CP) chronic myeloid leukemia (CML) has significantly improved due to the development of potent BCR::ABL1 tyrosine kinase inhibitors (TKIs). However, approximately 15‒20% of... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent advances in diagnosis and therapy in systemic mastocytosis
-
Lee HJ
- KMID: 2541988
- Blood Res.
- 2023 Apr;58(S1):96-108.
- doi: 10.5045/br.2023.2023024
Mastocytosis is a heterogeneous neoplasm characterized by accumulation of neoplastic mast cells in various organs. There are three main types: cutaneous mastocytosis (CM), systemic mastocytosis (SM), and mast cell sarcoma.... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor (CAR) T-cell therapy
-
Yoo JW
- KMID: 2541979
- Blood Res.
- 2023 Apr;58(S1):20-28.
- doi: 10.5045/br.2023.2023026
With impressive clinical advancements in immune effector cell therapies targeting CD19, chimeric antigen receptor (CAR) T-cell therapy has emerged as a new paradigm for treating relapsed/refractory B-cell malignancies. Currently, three... -
- CITED
-
- Close
- SHARE
-
- Close
